ATARA BIOTHERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $34.37 per share for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2018-05-08
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $34.37, a 130.83% increase year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $14.89, a 28.17% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $20.73, a 16.95% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $24.96.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $15.79, a 21.09% decline from fiscal 2016.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $20.01, a 30.88% decline from fiscal 2015.
- ATARA BIOTHERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $28.95.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2018-03-31 | $34.37 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $15.79 10-K · filed 2018-02-27 | |||
| 2017-09-30 | $15.99 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $16.53 10-Q · filed 2017-08-07 | |||
| 2017-03-31 | $14.89 10-Q · filed 2017-05-04 | |||
| 2016-12-31 | $20.01 10-K · filed 2017-03-09 | |||
| 2016-09-30 | $20.39 10-Q · filed 2016-11-04 | |||
| 2016-06-30 | $19.99 10-Q · filed 2016-08-08 | |||
| 2016-03-31 | $20.73 10-Q · filed 2016-05-06 | |||
| 2015-12-31 | $28.95 10-K · filed 2016-03-04 | |||
| 2015-09-30 | $33.57 10-Q · filed 2015-11-06 | |||
| 2015-06-30 | $27.09 10-Q · filed 2015-08-07 | |||
| 2015-03-31 | $24.96 10-Q · filed 2015-05-11 | |||
| 2014-09-30 | $12.55 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |